logo-loader
viewCircassia Pharmaceuticals PLC

Circassia's AirNOvent drug a step closer to market with FDA pre-submission meeting

Circassia Pharmaceuticals PLC (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott their partner, AIT Therapeutics Inc. has successfully completed a pre-submission meeting with the US FDA for the ventilator-compatible nitric oxide product AirNOvent.

AIT anticipates submitting a Premarket Approval application (PMA) for AirNOvent in the second quarter of 2019 for use in the treatment of hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn (PPHN).

Circassia intends launching the product in the first half of 2020, once approved.

Quick facts: Circassia Pharmaceuticals PLC

Price: 16.525 GBX

LSE:CIR
Market: LSE
Market Cap: £62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Pharmaceuticals PLC named herein, including the promotion by the Company of Circassia Pharmaceuticals PLC in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

3 weeks, 5 days ago

RNS

US launch of Duaklir at CHEST 2019

21 hours, 43 minutes ago

Grant of options

4 days, 11 hours ago

Holding(s) in Company

2 weeks, 4 days ago

Total Voting Rights

3 weeks, 1 day ago

Block listing Interim Review

3 weeks, 1 day ago

2 min read